Recruitment of the global first clinical data project of China Pharmaceutical Innovation and Investment Conference

Source: China pharmaceutical innovation promotion association 2017-09-05 the first "China Pharmaceutical Innovation and investment conference" was successfully held by China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "the association") and China Securities Association in 2016（ Hereinafter referred to as "the conference"), this year, the second conference jointly held by CFNA, China Securities Association and China Medical Device Industry Association will be held in Suzhou from October 29 to 31 The conference has had a significant impact at home and abroad The Chinese Academy of Medical Sciences, the Chinese Academy of traditional Chinese medicine and the Bureau of science and technology promotion and development of the Chinese Academy of sciences have confirmed that they will continue to be the supporting units of the conference; the internationally renowned financial institution JPMorgan Chase Bank of the United States will also be the supporting units of the conference; the Australia and the United States cancer research foundation will respectively open project Roadshows; Canada The embassy, the government of British Columbia, the Embassy of Israel, and the Taiwan biotechnology and medical industry promotion conference will organize innovation projects to participate in the roadshow Nature, a top international science magazine published by Springer nature group, will be the first professional media to report the whole process of the conference At the same time, the conference also attracted many well-known international financial media and domestic medical and investment professional media to report The conference includes opening ceremony, global launch of clinical data, domestic and international roadshows of drugs and medical devices, as well as innovation, policy and investor experience sharing forum and other related activities The conference will invite leaders of relevant departments of the state, as well as important celebrities from the pharmaceutical innovation and investment circles at home and abroad to attend the opening ceremony and deliver keynote speeches; the general manager of the stock exchange of Hong Kong will also attend the conference to introduce the upcoming Hong Kong Innovation Board The conference surpassed the first one in terms of scale, policy and technology authority and internationalization It is expected that the number of participants will reach 2000 Last year, the first clinical data launch session was held at the conference, with over one thousand participants Eight published projects have been favored by investment institutions, and some projects have been invested by them This year, the second congress will still hold a global debut of clinical data of innovative drugs after the opening ceremony on October 29 In order to show the clinical trial results of the most valuable innovative drugs at the conference, the Organizing Committee of the conference specially established a project review expert group composed of well-known clinical experts and innovative entrepreneurs with rich experience in drug research and development to ensure the high level and quality of the global first clinical data project This will help the investment community quickly and accurately understand the latest progress of innovative drugs and therapies, grasp the best investment opportunities in time, actively participate in pharmaceutical innovation, and achieve win-win cooperation The Organizing Committee of the conference is now widely soliciting new drug projects at home and abroad to complete clinical trials The deadline for application is September 30 The specific requirements for the global first launch of clinical data are as follows: 1 The first release of clinical trial data; 2 The results of clinical trials of drugs under research The innovative drugs declared for registration at home and abroad and the improved new drugs with more value than the existing therapies; the treatment field is unlimited; the clinical trials have been registered on the official website at home and abroad, and some or all of the phase I (tumor drugs), phase II and phase III trials have been completed 3 The results of clinical trials of listed drugs are innovative drugs approved to be listed in domestic or mainstream countries such as the United States, the European Union, Japan and other countries, as well as improved new drugs with more value than existing therapies; there is no limit to the field of treatment; they are registered on the official website of clinical trials at home and abroad, and have completed some or all post market trials Contact: Wang Min contact number: 010-58156402 email: wangm@phirda.com welcome enterprises and individuals who intend to participate in or recommend to participate in the global launch of clinical data to contact us September 5, 2017